CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

RegulatorypositiveOcrevusPositive

AI Analysis

Summary

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche's Ocrevus for treatment of relapsing multiple sclerosis in children and adolescents, expanding the drug's labeled indication.

Outcome Details

CHMP recommends EU approval

Importance:7/10

Sentiment:

0.85

EU approvalCHMP recommendationpediatric indicationmultiple sclerosisOcrevus

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 18, 2026 10:45 AM

Read Original